Table 8 Potential therapeutic tools for modulating complement activation, VEGFA/VEGFR2 Pathway, HSP90 and HIF-1α
Potential therapeutic | Formula | Targets | Mechanism of action | Refs |
|---|---|---|---|---|
Anti-C5a monoclonal antibody | C5a | A human monoclonal antibody | ||
PMX-53 | C47H65N11O7 | C5aR | An active C5aR antagonist | |
SB290157 trifluoroacetate | C24H29F3N4O6 | C3a | A selective C3aR antagonist | |
PMX 205 | C45H62N10O6 | C5aR | A C5aR antagonist. | |
Complement C5-IN-1 | C24H32N2O6 | C5 | A small-molecule inhibitor of C5 | |
SU5408 | C18H18N2O3 | VEGFR2 | A potent and cell-permeable inhibitor of VEGFR2 kinase | |
GW768505A | C27H19F4N5O3 | VEGFR2 | A potent inhibitor of VEGFR2 | |
Bevacizumab | VEGF | A humanized monoclonal antibody, specifically binds to all VEGFA isoforms with high affinity | ||
Ramucirumab | C285H434N74O88S2 | VEGFR2 | A recombinant human monoclonal antibody that binds to the extracellular binding domain of VEGFR2 and prevents the binding of VEGFR ligands | |
Alvespimycin | C32H48N4O8 | HSP90 | A potent inhibitor of Hsp90, binding to HSP90 | |
Retaspimycin Hydrochloride | C31H46ClN3O8 | HSP90 | A potent and water-soluble inhibitor of HSP90 | |
TAT-cyclo-CLLFVY TFA | C116H176N32O33 | HIF-1, VEGF | Inhibit hypoxia-induced HIF-1 activity, and decreases VEGF expression in vitro | |
Gramicidin A | C99H140N20O17 | HIF-1α | Induce degradation of HIF-1α. |
